Desk›Chemicals› Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd
BSE 543828 · NSE SUDARSHAN · ISIN INE00TV01023 · Group M · Active
Commodities › Chemicals › Chemicals & Petrochemicals › Specialty Chemicals
₹39.87
-0.10%
BSE close, 28 August 2026
₹995.39 cr
25.0 cr shares · Micro cap
₹407.15 cr
as published
45.3× · —
EPS ₹0.88 · BV —
667.50 / 21.98
₹ cr, as filed
23
9 selected · 39%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -6.8% |
|---|---|
| Against 52-week low | +115.5% |
| Day change | -0.10% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹0.88 |
|---|---|
| Price / earnings | 45.31× |
| Price / book | — |
| Book value — derived, price ÷ P/B | — |
| Return on equity | — |
| Operating margin | — |
| Net margin | — |
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Mar-26 · Q | 358.18 | 13.85 | 0.58 | 9.49% | 3.87% |
| Sep-25 · Q | 309.32 | 8.13 | 0.34 | 7.56% | 2.63% |
| FY25-26 | 667.50 | 21.98 | 0.91 | 8.60% | 3.29% |
Quarter on quarter
- Revenue, quarter on quarter
- +15.8%
- Net profit, quarter on quarter
- +70.4%
- Operating margin, quarter on quarter
- +193 bps
Disclosure profile 23 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Acquisition | 4 |
| Disinvestment | 2 |
| Investor Presentation | 2 |
| Results | 1 |
| Selected sub-total | 9 |
| Procedural | |
| SAST | 5 |
| AGM / EGM | 3 |
| Newspaper Publication | 2 |
| Allotment | 1 |
| Compliance Certificate | 1 |
| General | 1 |
| Trading Window | 1 |
| Procedural sub-total | 14 |
| Total | 23 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group M, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
23 filings · 9 selected · busiest 2026-08-13 and 2026-09-22
Filing rhythm · the twelve most recent
2026-08-262026-10-07
SelectedProcedural
Filings
23 in the window · 13 earlier on record
-
7 October 2026 ·
Updates on Acquisition
In continuation of the Company's letters dated 05/Sep/2026 and 15/Sep/2026, this is to inform you that the proposal to acquire 9.50% equity shares of common stock of Med Therapy Biotechnology ....
Company Update / Acquisition View filing →
-
7 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find attached copy of certificates under Regulation 74(5) of SEBI ( Depository And Participants ) Regulations, 2018, received from Kfin Technologies Limited for the quarter ended ....
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
30 September 2026 ·
Closure of Trading Window
The Trading Window of the Company shall remain closed with effect from October 1,2026 until the expiry of 48 hours after the declaration of financial results for the quarter and half year ....
Insider Trading / SAST / Closure of Trading Window View filing →
-
28 September 2026 ·
Diversification / Disinvestment
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in conitinuation of the Company's letter dated 13/Aug/2026 regarding stake sale ....
Company Update / Diversification / Disinvestment View filing →
-
22 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Please find enclosed the Scrutinizer's Report on the business transacted at the 18th Annual General Meeting of the company held on Tuesday 22/SEPT/2026 through video conferencing / other ....
AGM/EGM / AGM View filing →
-
22 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Please find enclosed the voting results on the business transacted at the 18th Annual General Meeting of the company held on Tuesday 22/SEPT/2026 at 3:00 p.m. through Video Conferencing/ ....
AGM/EGM / AGM View filing →
-
22 September 2026 ·
Proceedings Of Annual General Meeting Held On 22/SEPT/2026
Pursuant to Regulation 30 of SEBI ( Listing Obligations and Disclosure Requirements ) Regulations, 2015 we enclose herewith the summary of proceedings of the AGM.
AGM/EGM / AGM View filing →
-
15 September 2026 ·
Updates on Acquisition
Pursuant to Reg 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation of the Company letter no. SPIL/CS/2026-2027/57 dated 5th September 2026, ....
Company Update / Acquisition View filing →
-
9 September 2026 ·
Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 09, 2026 for Hemal V ....
Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 View filing →
-
9 September 2026 ·
Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 09, 2026 for Hemal Vasantrai Mehta
Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 View filing →
-
1 September 2026 ·
Newspaper Publication
Please find enclosed the newpaper advertisement for the Notice of 18th Annual General Meeting to be held on Yesday, 22nd September 2026 at 3.00 pm published in (1) Mumbai Lakshdeep (Marathi) ....
Company Update / Newspaper Publication View filing →
-
26 August 2026 ·
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 26, 2026 for Hemal V Mehta & Sachin V Mehta
Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 View filing →
-
19 August 2026 ·
Allotment
It is hereby informed that the members of the FCCB COmmittee of the COmpany, have at their meeting held today, 19/Aug/2026, have approved allotment of 48,11,730 fully paid-up equity shares ....
Company Update / Allotment of Equity Shares View filing →
-
18 August 2026 ·
Newspaper Publication
Please find enclosed the newspaper advertisement for the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/June/2026 published in (i) Mumbai Lakshdeep (Marathi) ....
Company Update / Newspaper Publication View filing →
-
18 August 2026 ·
Investor Presentation
Pursuant to Regulation 30 of SEBI LODR Regulations, We hereby submit the updated Investor Presentation
Company Update / Investor Presentation View filing →
-
17 August 2026 ·
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 14, 2026 for Vasantrai Ratilal ....
Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 View filing →
-
14 August 2026 ·
FCCB Committee Meeting On Wednesday, 19-August-2026
A Meeting of the FCCB Committee of the Company is scheduled on Wednesday, 19-August-2026 to consider and approve conversion a portion of funds raised through FCCBs into equity shares and ....
Company Update / General View filing →
-
14 August 2026 ·
Investor Presentation
We hereby submit the presentation on the manufacturing plant proposed to be acquired by the Company.
Company Update / Investor Presentation View filing →
-
13 August 2026 ·
Acquisition
The Company has entered into a Memorandum of Understanding to acquire 1,24,64,000 equity shares of Rs.10/- each of the target company (76% of paid up equity share capital). The acquisition ....
Company Update / Acquisition View filing →
-
13 August 2026 ·
Diversification / Disinvestment
The Board of Directors at their Meeting held on 12/August/2026 approved the divestment of 2,09,100 equity shares (51.00% of paid up share capital) of Ishwari Healthcare Private Limited. ....
Company Update / Diversification / Disinvestment View filing →
-
13 August 2026 ·
Acquisition
The Board of Directors at their meeting held on 12/August/2026 approved to acquire 3,000 equity shares (30.00% of paid up capital) of Sudarshan Maven Pharma Private Limited. Upon acqusition, ....
Company Update / Acquisition View filing →
-
12 August 2026 ·
Financial Results For The Quarter Ended 30/06/2026
Please find attached the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/06/2026
Result / Financial Results View filing →
-
10 August 2026 ·
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 08, 2026 for Hemal Vasantrai Mehta
Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011 View filing →
RSS feed for Sudarshan Pharma Industries Ltd · the 50 most recent filings